Ryvu Therapeutics has a track record of creating significant value for shareholders since its listing on the NewConnect market in 2011 and the subsequent IPO on the main market of Warsaw Stock Exchange in 2014. The company has delivered strong return on the combined $91M investment from private, public market investors, including over $36M raised in the Series I shares offering in July 2020. In December 2022, Ryvu closed an equity offering with gross proceeds over $56M from institutional and individual investors as well as BioNTech and The Leukemia & Lymphoma Society (LLS).

We value investor communications very highly and we build our investor relationships on trust and transparency. Ryvu is audited by EY and is subject to regulatory oversight of the Polish Financial Supervisory Authority, under the European Union and the Polish laws. Ryvu technological expertise is validated by global partnerships with BioNTech, Exelixis, Galapagos, Leukemia & Lymphoma Society, Menarini Group, and Merck KGaA.

In 2016, Ryvu has spun out its NALP3 inflammasome assets to NodThera, founded by life science investor, Epidarex Capital.  In total, the project aimed at the development of inflammasome inhibitors discovered by Ryvu and spun off to NodThera, has already raised over £80 million (over $98 million) of funding. Ryvu remains a shareholder in the Company. For more information about NodThera see: www.nodthera.com.

In August 2022, Ryvu has received €22 million in financing from The European Investment Bank (EIB) to accelerate the development of new therapies to treat severe blood cancers and solid tumours, including further clinical development of the flagship project RVU120.

Quick Access

Corporate Overview

Ryvu Milestones

2007
2010
2011
2013
2014
2015
2016
2017
2018
2019
2020
2021

2007

  • Company founded (as Selvita)

2010

  • First global partnering contract with Orion Pharma (as Selvita S.A.)

2011

  • Listed on NewConnect market (WSE)

2013

  • Beginning of oncology partnership with Merck KGaA

2014

  • IPO on Warsaw Stock Exchange

2015

  • Spin-out of Ardigen – precision medicine & AI services company

2016

  • Inflammasome assets spun-out to Nodthera

2017

  • Initiation of SEL24/MEN1703 study in acute myeloid leukemia
  • Global license agreement with Menarini Group for SEL24/MEN1703
  • Partnership with the Leukemia & Lymphoma society for RVU120 development

2018

  • Successful Completion of $41 M Book Building

2019

  • Ryvu divests its CRO business into Selvita
  • Initation of RVU120 study in acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS)

2020

  • SEL24/MEN1703 initiates Phase II studies
  • Orphan Drug Designation for RVU120 to treat Acute Myeloid Leukemia
  • Galapagos and Ryvu announce research collaboration
  • Ryvu moves to the newly built R&D Centre for Innovative Drugs
  • Completion of $36 M share issue
  • Expansion of SEL24/MEN1703 Phase I/II study to Europe

2021

  • Expansion of Phase I study of RVU120 in patients with AML or HRMDS to Poland

Contact For Investors

;